Collage Photo of Roupen Odabashian and Andre Esteva
Feb 5, 2025, 15:11
Roupen Odabashian: How ArteraAI is changing prostate cancer treatment through AI-powered diagnostics
Roupen Odabashian, Internal Medicine Physician and Hematology/Oncology Fellow at Karmanos Cancer Institute, shared a post on LinkedIn:
“In this exclusive interview, I sit down with Dr. Andre Esteva, CEO of ArteraAI, to explore how this pioneering MedTech company is changing prostate cancer treatment through AI-powered diagnostics.
Artera’s AI-driven tests, backed by rigorous clinical validation and major investors like Marc Benioff, are setting a new standard for personalized medicine. But how did they:
- Overcome the biggest hurdles in HealthTech?
- Secure insurance reimbursement and regulatory approvals?
- Seamlessly integrate AI into clinical workflows?
Dr. Esteva also shares powerful insights on:
- Building cross-functional teams in MedTech
- Fostering a values-driven company culture (lessons from Salesforce)
- Scaling AI innovations while keeping patient outcomes at the forefront
If you’re passionate about AI in Healthcare, Cancer Therapy, and Digital Health, this episode is a must-watch!
Listen Now:
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 5, 2025, 15:11
Feb 5, 2025, 15:07
Feb 5, 2025, 14:40
Feb 5, 2025, 14:37
Feb 5, 2025, 14:21
Feb 5, 2025, 14:02